← Back to Home

Gut Antibodies Can Also Put the Brakes on Cell Proliferation: Mouse Study Reveals a Defense Against Colon Tumors

IgA not only helps manage gut microbes but may also directly restrain cell division in the intestinal lining. Researchers identified the DMBT1 receptor involved in this defense, but whether oral antibodies can prevent human colon cancer remains to be verified.

By SURL BioNews

The intestinal lining must continually renew itself to withstand daily contact with food and microbes, yet cell division also needs to be kept in check. A team at Rockefeller University found that immunoglobulin A (IgA), an antibody commonly found in the gut, may be one line of defense that maintains this balance: through the DMBT1 receptor on the surface of epithelial cells, it can suppress excessive proliferation and reduce the tendency of mice to develop colon tumors.

In its November 11 account of the study published in *Nature*, the university reported that mice lacking IgA had more than twice as many colon tumors as normal mice; after oral IgA supplementation, the excess susceptibility to tumors was no longer observed. This means the antibody had a protective effect in the experiments, but it does not mean that supplementation eliminated all tumors or cured existing ones.

The research initially focused on interactions between IgA and gut bacteria. The team housed IgA-deficient and normal mice together so that they were exposed to similar microbes and food, and observed results pointing in the same direction across different colon cancer models. Further analysis showed that, even before tumors appeared, the intestinal epithelium of IgA-deficient mice already exhibited changes in gene expression related to cell division, pointing to tissue regulation before tumor formation.

DMBT1 provided a concrete mechanism for this finding. According to the university, DMBT1 promotes epithelial cell proliferation in the presence of gut bacteria; when IgA binds to it, this signal can be suppressed. In other words, beyond interacting with microbes, the antibody can directly regulate how the intestinal lining responds to them, preventing normal renewal needs from developing into excessive cell division.

An earlier preprint of the same study provided more experimental details. Combining mass spectrometry with a targeted CRISPR screen, the researchers identified DMBT1 as a cell-surface protein required for IgA to suppress epithelial growth; organoids and monolayer cell cultures also supported a direct effect of IgA on epithelial growth. That version also reported that the protective effect depended on the antibody’s structure rather than its ability to recognize specific antigens, suggesting that this function may not require targeting a particular pathogen.

The preprint also linked this regulatory mechanism to Notch signaling: removing DMBT1’s transmembrane and intracellular signaling regions, or blocking Notch signaling, could reverse the increased proliferation and tumor susceptibility in IgA-deficient mice. However, the 2024 version available in PubMed Central is explicitly marked as not yet peer reviewed. These details should be treated as evidence from an earlier version and cannot automatically be assumed to be identical to the formally published content.

The finding suggests an avenue for further investigation in cancer prevention: adjusting how epithelial cells receive and respond to signals from the gut before tumors form. However, the evidence remains primarily based on mouse and cell experiments. It has not yet been shown that oral IgA can reduce the risk of human colon cancer, nor have a dose, method of administration, or long-term safety for preventive use been established. Key steps remain between understanding the gut’s natural defenses and translating that understanding into a clinical intervention.

References

  1. The Rockefeller University
  2. bioRxiv via PubMed Central